ArticleNature communications2020
Enhancing myocardial repair with CardioClusters.
Article in Nature communications, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 36 citations in OpenAlex.
- Age-associated T cell immunity decreases circulating endothelial progenitor cells.Stem cells (Dayton, Ohio) · 2026Article
- Scalable differentiation of human cardiac organoids from iPSCs generates cardiac tissues for cardiac cell therapy.Theranostics · 2026Article
- Key Steps in Murine Cardiac Engineering Validation: How Does It Affect the Efficiency of Cardiac Devices?BioMed research international · 2026Review
- Intravenous mesenchymal stem cell transplantation mitigates pulmonary vascular remodeling but poses dose related risks in a pulmonary veno-occlusive disease model.Stem cell research & therapy · 2025Article
- Pop-Out Myocardial Infarction Induction in Mice.Methods in molecular biology (Clifton, N.J.) · 2024Article
- Non-human primate studies for cardiomyocyte transplantation-ready for translation?Frontiers in pharmacology · 2024Review
- Targeting the redox system for cardiovascular regeneration in aging.Aging cell · 2023Review
- C-kitHeliyon · 2023Article
- Article
- Engineered Tissue for Cardiac Regeneration: Current Status and Future Perspectives.Bioengineering (Basel, Switzerland) · 2022Review
- Mesenchymal Stromal Cells Overexpressing Farnesoid X Receptor Exert Cardioprotective Effects Against Acute Ischemic Heart Injury by Binding Endogenous Bile Acids.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2022Article
- Clinical assessment and molecular mechanism of the upregulation of Toll-like receptor 2 (TLR2) in myocardial infarction.BMC cardiovascular disorders · 2022Article
- Atypically Shaped Cardiomyocytes (ACMs): The Identification, Characterization and New Insights into a Subpopulation of Cardiomyocytes.Biomolecules · 2022Review
- Review
- hESCs-Derived Early Vascular Cell Spheroids for Cardiac Tissue Vascular Engineering and Myocardial Infarction Treatment.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2022Article
- Cardiac stem cells: Current knowledge and future prospects.World journal of stem cells · 2022Review
- Article
- A small erythropoietin derived non-hematopoietic peptide reduces cardiac inflammation, attenuates age associated declines in heart function and prolongs healthspan.Frontiers in cardiovascular medicine · 2022Article
- Hybrid SMART spheroids to enhance stem cell therapy for CNS injuries.Science advances · 2021Article
- Recent Advances in Cardiac Tissue Engineering for the Management of Myocardium Infarction.Cells · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 1 institution in 1 country.
Funding
Abstract
Cellular therapy to treat heart failure is an ongoing focus of intense research, but progress toward structural and functional recovery remains modest. Engineered augmentation of established cellular effectors overcomes impediments to enhance reparative activity. Such 'next generation' implementation includes delivery of combinatorial cell populations exerting synergistic effects. Concurrent isolation and expansion of three distinct cardiac-derived interstitial cell types from human heart tissue, previously reported by our group, prompted design of a 3D structure that maximizes cellular interaction, allows for defined cell ratios, controls size, enables injectability, and minimizes cell loss. Herein, mesenchymal stem cells (MSCs), endothelial progenitor cells (EPCs) and c-Kit
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.